The Effect of Sample Medication Use on Subsequent Anti-VEGF Agent Selection for Neovascular Age-Related Macular Degeneration. (17th November 2022)

• Record Type: Journal Article
• Authors: Wai, Karen M.; Begaj, Tedi; Patil, Sachi; Chen, Evan M.; Miller, John B.; Kylstra, Jan; Aronow, Mary E.; Young, Lucy H.; Huckfeldt, Rachel; Husain, Deeba; Kim, Leo A.; Vavvas, Demetrios G.; Eliott, Dean; Mukai, Shizuo; Gragoudas, Evangelos S.; Patel, Nimesh A.; Sobrin, Lucia; Miller, Joan W.; Parikh, Ravi; Wu, David M.
• Is Part Of: Seminars in ophthalmology. Volume 37:Number 7/8(2022)
• Page Start: 902
• Page End: 908
• Publication Date: 2022-11-17
• Subjects: Anti-VEGF agents -- anti-VEGF sample -- Intravitreal injection -- Sample medications -- Wet age-related macular degeneration; Ophthalmology -- Periodicals; Eye -- Diseases -- Periodicals; Eye -- Surgery -- Periodicals; 617.7005
• DOI: 10.1080/08820538.2022.2107398
• Languages: English
• ISSNs: 0882-0538

Abstract

ABSTRACT: Purpose: Medication samples of anti-VEGF agents can represent a good option for retina specialists to provide timely treatment for newly converted neovascular age-related macular degeneration (nvAMD) while prior-authorizations (PA) are pending. Our study examines the effect of medication sample use (ranibizumab or aflibercept) on future anti-vascular endothelial growth factor (VEGF) agent selection in nvAMD. Design: Retrospective cohort study. Participants: nvAMD patients who underwent an initial anti-VEGF injection with a sample medication were compared to nvAMD control patients who never received a medication sample. Methods: Charts from 2017 through 2020 were reviewed for data regarding demographics, anti-VEGF agent selection, and visual acuity outcomes for both groups. The utilization of different anti-VEGF agents in each group was compared at various time points using chi-square tests for independence of proportions. Main Outcome Measures: Anti-VEGF agent selection for the first four injections and at one year were examined. Results: Adherence to the initial agent was high between first and subsequent injections (2 nd, 3 rd, 4 th injection, and 1 year) in sample (96.2%, 95.9%, 91.9%, 93.4%, respectively), and control groups (98.1%, 94.2%, 94.9%, 87.8%, respectively). Bevacizumab usage was significantly lower among eyes receiving samples relative to controls at the second (1.9% vs. 38.7%, p < .001), third (3.1% vs. 41.3%, p < .001), fourth injections (4.7% vs. 40.4%, p < .001), and at 1 year (0% vs. 33.8%, p < .001). Aflibercept usage was significantly higher in sample eyes relative to controls at the second (78.3% vs. 43.4%, p < .001), third (76.3% vs. 41.5%, p < .001), and fourth injections (76.7% vs. 43.4%, p < .001), and at 1 year (77.0% vs. 52.7%, p < .001). Conclusions: Sample medications in nvAMD may be initiated for many reasons, including awaiting PA approval. Our study found that eyes receiving a sample anti-VEGF agent (ranibizumab or aflibercept) for their initial injection were less likely to receive bevacizumab at future visits relative to eyes that did not receive an anti-VEGF sample, even after one year of treatment. Given the persistent use of more expensive medications at subsequent injections for patients who were initiated on samples, insurance payors may consider waiving PA requirements for bevacizumab to avoid a paradoxical increase in health-care costs.